{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T05:14:20Z","timestamp":1735967660001,"version":"3.32.0"},"reference-count":30,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:p>These case studies review the treatment of patients with overactive bladder (OAB), a chronic condition presenting with urinary urgency, often occurring with frequency and nocturia, which may or may not be associated with urinary incontinence. Patients with OAB can have multiple clinical\n factors to consider when selecting the optimal therapy, and this treatment series provides examples of approaches to balance treatment selection with other comorbidities and patient expectations.<\/jats:p>","DOI":"10.4140\/tcp.n.2025.10","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:31:08Z","timestamp":1735878668000},"page":"10-17","source":"Crossref","is-referenced-by-count":0,"title":["Complicated Overactive Bladder Management"],"prefix":"10.4140","volume":"40","author":[{"given":"Kaylee","family":"Mehlman","sequence":"first","affiliation":[{"name":"1 Geramed Senior Care Consulting, Brunswick, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Nalls","sequence":"additional","affiliation":[{"name":"2 CareBridge, Nashville, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Wessel","sequence":"additional","affiliation":[{"name":"3 Pharma-Care Inc, Clark, New Jersey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/nau.23277","article-title":"Severe depression and anxiety in women with overactive bladder","volume":"37","year":"2018","journal-title":"Neurourol Urodyn"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","article-title":"Real-world characteristics of elderly patients with overactive bladder in the United States","volume":"32","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","article-title":"Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting","volume":"109","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"ref4","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics","volume":"22","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"ref5","volume-title":"Diagnosis and Treatment of Overactive Bladder (non-neurogenic) in Adults: AUA\/SUFU Guideline","year":"2019"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis","volume":"40","year":"2021","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/nau.25037","article-title":"SUFU white paper on overactive bladder anticholinergic medications and dementia risk","volume":"41","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/SPV.0000000000001008","article-title":"Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder","volume":"27","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"ref12","volume-title":"MYRBETRIQ\u00ae (mirabegron extended-release tablets) [package insert]","year":"2018"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"ref14","volume-title":"Clinical Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-mediated Drug Interactions Guidance for Industry","year":"2020"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/96286","article-title":"Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders","volume":"53","year":"2019","journal-title":"Psychiatr Pol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13318-014-0205-x","article-title":"A metoprololterbinafine combination induced bradycardia","volume":"40","year":"2015","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1007\/s12325-021-01902-8","article-title":"Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison","volume":"38","year":"2021","journal-title":"Adv Ther"},{"key":"ref18","first-page":"2022","article-title":"Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis","volume":"11","year":"2022","journal-title":"Drugs Context"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MBP.0000000000000572","article-title":"Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial","volume":"27","year":"2022","journal-title":"Blood Press Monit"},{"key":"ref20","volume-title":"GEMTESA\u00ae (vibegron) [package insert]","year":"2023"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40273-022-01163-5","article-title":"Budget impact analysis of vibegron for the treatment of overactive bladder in the USA","volume":"40","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1177\/000348940711601112","article-title":"Dysphagia in the elderly: preliminary evidence of prevalence, risk factors, and socioemotional effects","volume":"116","year":"2007","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"21955","DOI":"10.1038\/s41598-021-99858-w","article-title":"Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs","volume":"11","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"ref24","first-page":"62","article-title":"Anticholinergic burden and dry mouth in middle-aged people","volume":"5","year":"2020","journal-title":"JDR Clin Trans Res"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","article-title":"Empagliflozin induces transient diuresis without changing long-term overall fluid balance in japanese patients with type 2 diabetes","volume":"9","year":"2018","journal-title":"Diabetes Ther"},{"key":"ref28","volume-title":"Jardiance (empagliflozin) [package insert]","year":"2023"},{"issue":"4","key":"ref29","first-page":"311","article-title":"Deprescribing in palliative care","volume":"19","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"ref30","volume-title":"Aricept\u00ae (donepezil hydrochloride) [package insert]","year":"1996"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000001\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:32:09Z","timestamp":1735878729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["2639-9636(20250101)40:1L.10;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.10","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}